Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00625664




Registration number
NCT00625664
Ethics application status
Date submitted
19/02/2008
Date registered
28/02/2008
Date last updated
5/05/2016

Titles & IDs
Public title
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Scientific title
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Secondary ID [1] 0 0
EUDRACT: 2007-001943-23
Secondary ID [2] 0 0
EFC6668
Universal Trial Number (UTN)
Trial acronym
CILAB
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - larotaxel (XRP9881)
Treatment: Drugs - gemcitabine
Treatment: Drugs - cisplatin

Experimental: 1 -

Active comparator: 2 -


Treatment: Drugs: larotaxel (XRP9881)
administered on day 1 as a 1-hour infusion

Treatment: Drugs: gemcitabine
administered on day 1, 8 and 15 as a 30-minute infusion

Treatment: Drugs: cisplatin
1 hour infusion administered on day 1, 30 minutes after the other treatment
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival defined as the time interval from the date of randomization to the date of death due to any cause
Timepoint [1] 0 0
study period
Secondary outcome [1] 0 0
Radiological tumor assessments (CT/MRI)
Timepoint [1] 0 0
at screening, every 8 weeks during treatment, at end of treatment, and in follow-up until documented disease progression
Secondary outcome [2] 0 0
Adverse Events, laboratory assessments, vital signs, Physical Examinations, and ECOG Performance Status
Timepoint [2] 0 0
at screening and every cycle

Eligibility
Key inclusion criteria
* Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) with locally advanced (T4b) or metastatic urothelial tract or bladder cancer
* ECOG Performance Status 0 or 1
* No prior palliative chemotherapy
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* (Neo)Adjuvant chemotherapy if < 6 months between end of (neo)adjuvant chemotherapy and relapse
* Less than 6 weeks elapsed from prior radiotherapy and less than 3 weeks from surgery to time of randomization
* Prior cisplatin as (neo)adjuvant chemotherapy with cumulative dose > 300 mg/m²

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2011
Sample size
Target
Accrual to date
Final
337
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Sanofi-Aventis Investigational Site Number 036002 - Adelaide
Recruitment hospital [2] 0 0
Sanofi-Aventis Investigational Site Number 036003 - Bedford Park
Recruitment hospital [3] 0 0
Sanofi-Aventis Investigational Site Number 036004 - St Leonards
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
2065 - St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alaska
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Rhode Island
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad De Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Mendoza
Country [30] 0 0
Argentina
State/province [30] 0 0
Rosario
Country [31] 0 0
Argentina
State/province [31] 0 0
Santa Fe
Country [32] 0 0
Belgium
State/province [32] 0 0
Aalst
Country [33] 0 0
Belgium
State/province [33] 0 0
Bruxelles
Country [34] 0 0
Belgium
State/province [34] 0 0
Ottignies
Country [35] 0 0
Belgium
State/province [35] 0 0
Wilrijk
Country [36] 0 0
Belgium
State/province [36] 0 0
Yvoir
Country [37] 0 0
Brazil
State/province [37] 0 0
Barretos
Country [38] 0 0
Brazil
State/province [38] 0 0
Florianopolis
Country [39] 0 0
Brazil
State/province [39] 0 0
Porto Alegre
Country [40] 0 0
Brazil
State/province [40] 0 0
Rio De Janeiro
Country [41] 0 0
Brazil
State/province [41] 0 0
Sao Paulo
Country [42] 0 0
Canada
State/province [42] 0 0
Edmonton
Country [43] 0 0
Canada
State/province [43] 0 0
London
Country [44] 0 0
Canada
State/province [44] 0 0
Montreal
Country [45] 0 0
Canada
State/province [45] 0 0
Quebec
Country [46] 0 0
Canada
State/province [46] 0 0
Weston
Country [47] 0 0
Chile
State/province [47] 0 0
Santiago
Country [48] 0 0
France
State/province [48] 0 0
Avignon
Country [49] 0 0
France
State/province [49] 0 0
Bordeaux Cedex
Country [50] 0 0
France
State/province [50] 0 0
Hyeres
Country [51] 0 0
France
State/province [51] 0 0
Le Mans
Country [52] 0 0
France
State/province [52] 0 0
Lyon
Country [53] 0 0
France
State/province [53] 0 0
Perpignan
Country [54] 0 0
France
State/province [54] 0 0
Poitiers Cedex
Country [55] 0 0
France
State/province [55] 0 0
Saint Herblain
Country [56] 0 0
France
State/province [56] 0 0
Strasbourg
Country [57] 0 0
France
State/province [57] 0 0
Suresnes
Country [58] 0 0
India
State/province [58] 0 0
Bangalore
Country [59] 0 0
India
State/province [59] 0 0
Kolkata
Country [60] 0 0
India
State/province [60] 0 0
New Delhi
Country [61] 0 0
India
State/province [61] 0 0
Vellore
Country [62] 0 0
India
State/province [62] 0 0
Vishakhapatnam
Country [63] 0 0
Israel
State/province [63] 0 0
Haifa
Country [64] 0 0
Israel
State/province [64] 0 0
Kfar Saba
Country [65] 0 0
Israel
State/province [65] 0 0
Petah-Tikva
Country [66] 0 0
Israel
State/province [66] 0 0
Tel Aviv
Country [67] 0 0
Israel
State/province [67] 0 0
Tel Hashomer
Country [68] 0 0
Israel
State/province [68] 0 0
Tzrifin
Country [69] 0 0
Italy
State/province [69] 0 0
Bari
Country [70] 0 0
Italy
State/province [70] 0 0
Lecce
Country [71] 0 0
Italy
State/province [71] 0 0
Meldola
Country [72] 0 0
Italy
State/province [72] 0 0
Pavia
Country [73] 0 0
Italy
State/province [73] 0 0
Perugia
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Italy
State/province [75] 0 0
Viterbo
Country [76] 0 0
Mexico
State/province [76] 0 0
Aguascalientes
Country [77] 0 0
Mexico
State/province [77] 0 0
Chihuahua
Country [78] 0 0
Mexico
State/province [78] 0 0
Monterrey
Country [79] 0 0
Netherlands
State/province [79] 0 0
Amsterdam
Country [80] 0 0
Netherlands
State/province [80] 0 0
Arnhem
Country [81] 0 0
Netherlands
State/province [81] 0 0
Hoofddorp
Country [82] 0 0
Netherlands
State/province [82] 0 0
Maastricht
Country [83] 0 0
Netherlands
State/province [83] 0 0
Nijmegen
Country [84] 0 0
Netherlands
State/province [84] 0 0
Sittard-Geleen
Country [85] 0 0
Netherlands
State/province [85] 0 0
Zwolle
Country [86] 0 0
Poland
State/province [86] 0 0
Poznan
Country [87] 0 0
Poland
State/province [87] 0 0
Rybnik
Country [88] 0 0
Poland
State/province [88] 0 0
Warszawa
Country [89] 0 0
Poland
State/province [89] 0 0
Wroclaw
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Chelyabinsk
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Kursk
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Moscow
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Obninsk
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Saint-Petersburg
Country [95] 0 0
Russian Federation
State/province [95] 0 0
St-Petersburg
Country [96] 0 0
South Africa
State/province [96] 0 0
Bloemfontein
Country [97] 0 0
South Africa
State/province [97] 0 0
Cape Town
Country [98] 0 0
South Africa
State/province [98] 0 0
Durban
Country [99] 0 0
South Africa
State/province [99] 0 0
Port Elizabeth
Country [100] 0 0
South Africa
State/province [100] 0 0
Pretoria
Country [101] 0 0
Spain
State/province [101] 0 0
Badalona
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid
Country [104] 0 0
Spain
State/province [104] 0 0
Oviedo
Country [105] 0 0
Spain
State/province [105] 0 0
Palma De Mallorca
Country [106] 0 0
Spain
State/province [106] 0 0
Pamplona
Country [107] 0 0
Spain
State/province [107] 0 0
Santiago De Compostela
Country [108] 0 0
Spain
State/province [108] 0 0
Zaragoza
Country [109] 0 0
Sweden
State/province [109] 0 0
Umeå
Country [110] 0 0
Sweden
State/province [110] 0 0
Uppsala
Country [111] 0 0
Turkey
State/province [111] 0 0
Ankara
Country [112] 0 0
Turkey
State/province [112] 0 0
Istanbul

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, open-label, multi-center study comparing the efficacy and safety of XRP9881 plus cisplatin to gemcitabine plus cisplatin in the first line treatment of locally advanced/metastatic urothelial tract or bladder cancer. The primary objective is to compare overall survival. Secondary objectives include comparisons of progression free survival, objective response rate, time to definitive deterioration of performance status, duration of response, time to definitive weight loss, and assessments of overall safety, and pharmacokinetics. Patients are treated until disease progression, death, or unacceptable toxicity and are followed-up until death or the end of the study whichever comes first.
Trial website
https://clinicaltrials.gov/study/NCT00625664
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00625664